DNA Repair and Damage Pathways in Mesothelioma Development and Therapy

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2022 May 3

PMID 35501851

Authors

Faezeh Malakoti

Niloufar Targhazeh

Erfan Abadifard

Reza Zarezadeh

Sahar Samemaleki

Zatollah Asemi

Simin Younesi

Reza Mohammadnejad

Seyed Hadi Hossini

Ansar Karimian

Forough Alemi

Bahman Yousefi

Affiliations

Soon will be listed here.

Abstract

Malignant mesothelioma (MMe) is an aggressive neoplasm that occurs through the transformation of mesothelial cells. Asbestos exposure is the main risk factor for MMe carcinogenesis. Other important etiologies for MMe development include DNA damage, over-activation of survival signaling pathways, and failure of DNA damage response (DDR). In this review article, first, we will describe the most important signaling pathways that contribute to MMe development and their interaction with DDR. Then, the contribution of DDR failure in MMe progression will be discussed. Finally, we will review the latest MMe therapeutic strategies that target the DDR pathway.

Citing Articles

Recent Advances in Mesothelioma Treatment: Immunotherapy, Advanced Cell Therapy, and Other Innovative Therapeutic Modalities.

Suraya R, Nagano T, Tachihara M Cancers (Basel). 2025; 17(4).

PMID: 40002287 PMC: 11853238. DOI: 10.3390/cancers17040694.

Differential expression of transcripts as a novel prognostic biomarker in histologically diverse mesotheliomas.

Alnassar N, Derry J, Banna G, Gorecki D Transl Lung Cancer Res. 2024; 13(4):733-748.

PMID: 38736495 PMC: 11082705. DOI: 10.21037/tlcr-24-28.

Inflammatory signaling pathways in the treatment of Alzheimer's disease with inhibitors, natural products and metabolites (Review).

Zheng Y, Zhang X, Zhang R, Wang Z, Gan J, Gao Q Int J Mol Med. 2023; 52(5).

PMID: 37800614 PMC: 10558228. DOI: 10.3892/ijmm.2023.5314.

Epithelioid Mesothelioma Patients with Very Long Survival Display Defects in DNA Repair.

Ganzinelli M, Guffanti F, Ianza A, Sobhani N, Crovella S, Zanconati F Cancers (Basel). 2023; 15(17).

PMID: 37686585 PMC: 10486625. DOI: 10.3390/cancers15174309.

The Genes-Stemness-Secretome Interplay in Malignant Pleural Mesothelioma: Molecular Dynamics and Clinical Hints.

Stella G, Marchio C, Bari E, Ferrarotti I, Bertuccio F, Di Gennaro A Int J Mol Sci. 2023; 24(4).

PMID: 36834912 PMC: 9963101. DOI: 10.3390/ijms24043496.

References

Malakoti F, Alemi F, Younesi S, Majidinia M, Yousefi B, Morovat P . The cross-talk between signaling pathways, noncoding RNAs and DNA damage response: Emerging players in cancer progression. DNA Repair (Amst). 2021; 98:103036. DOI: 10.1016/j.dnarep.2020.103036. View

Heller E, Hurchla M, Xiang J, Su X, Chen S, Schneider J . Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment. Cancer Res. 2011; 72(4):897-907. PMC: 3659806. DOI: 10.1158/0008-5472.CAN-11-2681. View

Blum W, Pecze L, Felley-Bosco E, Schwaller B . Overexpression or absence of calretinin in mouse primary mesothelial cells inversely affects proliferation and cell migration. Respir Res. 2015; 16:153. PMC: 4699379. DOI: 10.1186/s12931-015-0311-6. View

Sundaresan N, Pillai V, Wolfgeher D, Samant S, Vasudevan P, Parekh V . The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy. Sci Signal. 2011; 4(182):ra46. DOI: 10.1126/scisignal.2001465. View

Dai L, Dai Y, Han J, Huang Y, Wang L, Huang J . Structural insight into BRCA1-BARD1 complex recruitment to damaged chromatin. Mol Cell. 2021; 81(13):2765-2777.e6. DOI: 10.1016/j.molcel.2021.05.010. View

Gotzos V, Vogt P, Celio M . The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type. Pathol Res Pract. 1996; 192(2):137-47. DOI: 10.1016/S0344-0338(96)80208-1. View

You M, Varona-Santos J, Singh S, Robbins D, Savaraj N, Nguyen D . Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro. J Thorac Cardiovasc Surg. 2013; 147(1):508-16. DOI: 10.1016/j.jtcvs.2013.08.035. View

Pacurari M, Yin X, Zhao J, Ding M, Leonard S, Schwegler-Berry D . Raw single-wall carbon nanotubes induce oxidative stress and activate MAPKs, AP-1, NF-kappaB, and Akt in normal and malignant human mesothelial cells. Environ Health Perspect. 2008; 116(9):1211-7. PMC: 2535624. DOI: 10.1289/ehp.10924. View

DIncalci M, Badri N, Galmarini C, Allavena P . Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. Br J Cancer. 2014; 111(4):646-50. PMC: 4134488. DOI: 10.1038/bjc.2014.149. View

10.

Srinivasan G, Sidhu G, Williamson E, Jaiswal A, Najmunnisa N, Wilcoxen K . Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition. Cancer Chemother Pharmacol. 2017; 80(4):861-867. PMC: 5608777. DOI: 10.1007/s00280-017-3401-y. View

11.

Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, De Vuyst P . Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2009; 35(3):479-95. DOI: 10.1183/09031936.00063109. View

12.

Handra-Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau-St-Guily J, Soria J . Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell.... Clin Cancer Res. 2007; 13(13):3855-9. DOI: 10.1158/1078-0432.CCR-07-0252. View

13.

Altomare D, Menges C, Xu J, Pei J, Zhang L, Tadevosyan A . Losses of both products of the Cdkn2a/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis. PLoS One. 2011; 6(4):e18828. PMC: 3079727. DOI: 10.1371/journal.pone.0018828. View

14.

Cleary J, Aguirre A, Shapiro G, DAndrea A . Biomarker-Guided Development of DNA Repair Inhibitors. Mol Cell. 2020; 78(6):1070-1085. PMC: 7316088. DOI: 10.1016/j.molcel.2020.04.035. View

15.

Yang Y, Sun F, Chen H, Tan H, Yang L, Zhang L . Postnatal exposure to DINP was associated with greater alterations of lipidomic markers for hepatic steatosis than DEHP in postweaning mice. Sci Total Environ. 2020; 758:143631. DOI: 10.1016/j.scitotenv.2020.143631. View

16.

Monk B, Ghatage P, Parekh T, Henitz E, Knoblauch R, Matos-Pita A . Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study. Ann Oncol. 2015; 26(5):914-920. DOI: 10.1093/annonc/mdv071. View

17.

Menges C, Sementino E, Talarchek J, Xu J, Chernoff J, Peterson J . Group I p21-activated kinases (PAKs) promote tumor cell proliferation and survival through the AKT1 and Raf-MAPK pathways. Mol Cancer Res. 2012; 10(9):1178-88. PMC: 3447107. DOI: 10.1158/1541-7786.MCR-12-0082. View

18.

Arulananda S, Thapa B, Walkiewicz M, Zapparoli G, Williams D, Dobrovic A . Mismatch Repair Protein Defects and Microsatellite Instability in Malignant Pleural Mesothelioma. J Thorac Oncol. 2018; 13(10):1588-1594. DOI: 10.1016/j.jtho.2018.07.015. View

19.

Carbone M, Kratzke R, Testa J . The pathogenesis of mesothelioma. Semin Oncol. 2002; 29(1):2-17. DOI: 10.1053/sonc.2002.30227. View

20.

Toumpanakis D, Theocharis S . DNA repair systems in malignant mesothelioma. Cancer Lett. 2011; 312(2):143-9. DOI: 10.1016/j.canlet.2011.08.021. View